This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EDAP Reports Publication Of Long-Term Clinical Results For Largest Cohort Of Ablatherm-HIFU Patients

LYON, France, Sept. 8, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU. A total of 803 patients with localized prostate cancer, treated with Ablatherm-HIFU from 1993 until 2007, were reported in a study carried out by Dr. Sébastien Crouzet, Urologist at Edouard Herriot Hospital, Lyon, France. The analysis has been published electronically by the medical journal European Urology, the official scientific publication of the European Association of Urology, and will appear in an upcoming print edition of European Urology. These results were recently presented by Dr. Crouzet at the World Congress of Endourology in Chicago.

This French multi-centric study reports the largest series of patients who have been followed for the longest amount of time. The durability of efficacy outcomes of robotic Ablatherm-HIFU in the treatment of localized prostate cancer is now established out to eight years. Clinical results obtained using Ablatherm-HIFU were favorable. For a representative number of patients with a minimum of two year follow-up and a maximum of 15 years, the cancer specific survival rate and the freedom from metastatic disease rate were 99% and 97%, respectively, at eight years. In this study, the local control of the disease was achieved with an 85% rate of negative biopsies and a biochemical disease free survival rate (Phoenix criteria) of 83% in low risk cancer patients.

These results build upon those already published in 2006 from a cohort of 297 patients treated with Ablatherm-HIFU at Edouard Herriot Hospital in Lyon, France. The data clearly demonstrates efficacy and stability of Ablatherm-HIFU approach in the treatment of localized prostate cancer.

Dr. Sébastien Crouzet commented, "Ablatherm-HIFU long term results compiled in this study were very positive in terms of efficacy. The clinical outcomes clearly demonstrate stability and efficacy over time using this robotic non-operator dependant approach. Based on these positive findings, Ablatherm-HIFU should be offered to a younger and wider patient population suffering from localized prostate cancer, as it would preserve their quality of life by avoiding risk, such as incontinence and impotence."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
EDAP $3.48 0.29%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs